CSI Market
Sign In | Register

Prourocare Medical (PUMD) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access PUMD quarterly Cash Flow →
This cash flow overview for Prourocare Medical spans from to Dec 31 2012, illustrating how cash generation and usage have shifted across recent reporting periods.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2012)
12 Months 		(Dec 31 2010) (Dec 31 2012)
Operating Activities
Income-2.96
Depreciation & amortization0.00
Amortization of Other Assets0.14
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation0.03
Income (Loss) from Equity Method Investments0.00
Adjustment of Warrants Granted for Services-0.14
Depreciation And Amortization Excluding Amortization Of Financing Costs And Deferred Charges-
Common Stock Issued For Debt Guarantees-
Common Stock Issued For Debt Issuance Cost-
Common Stock Issued For Debt Extinguishment-
Notes Payable Issued For Intangibles Expensed As Research And Development-
Convertible Note Issued For Services Rendered-
Warrants Issued For Debt Extinguishment Related Parties-
Issuance Of Warrant As Debt Issuance Cost-
Warrants Issued For Early Warrant Exercise Incentive-
Units Issued For Interest Expense-
Units Issued For Debt Extinguishment-
Amortization Of Note Payablerelated Parties Original Issue Discount-
Amortization Of Convertible Debt Original Issue Discount-
Amortization Of Convertible Debt Related Parties Original Issue Discount-
Write Off Of Deferred Debt Issuance Cost-
Write Off Of Deferred Offering Cost-
Issuance Of Common Stock To Acquire Technology Rights Issue One-
Issuance Of Common Stock To Acquire Technology Rights Issue Two-
Increase Decrease In Accrued Development Expense0.52
Income taxes0.86
Losses/ -gains on Investments net0.00
Accounts Receivable0.00
Increase (Decrease) in Accounts Payable0.20
Increase (Decrease) in Other Accrued Liabilities0.18
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense0.01
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities0.00
Discontinued operations0.00
Net Cash flow from Operating Activities-1.12
Investing Activities
Capital Expenditures-0.01
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Payments to Acquire Restricted Certificates of Deposit0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-0.01
Financing Activities
Short-term debt Net-0.05
Other borrowing transactions0.00
Long-term debt - borrowings0.20
Long-term debt - repayments-0.10
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.89
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Proceeds Of Notes Payable Related Parties0.25
Payments Of Notes Payable Related Parties-0.01
Advances From Related Parties-
Proceeds From Debt Subscription Agreement-
Payments Of Convertible Notes Payable-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities1.18
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-1.13
Total Cash Flow0.05
4 historic quarters locked

Sign in to unlock the full Prourocare Medical cash flow history.

Sign In Create Free Account

About PUMD Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

  • Form: 10-K
  • Filed with the SEC: n/a

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document 





                    


    



  Get the full CSIMarket dataset:
  Subscribe
  API
  License